Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations

20133,182 citationsJournal Article

Authors

Lecia V. Sequist

James Chih‐Hsin Yang

Sarayut Lucien Geater

Abstract

Afatinib is associated with prolongation of PFS when compared with standard doublet chemotherapy in patients with advanced lung adenocarcinoma and EGFR mutations.

Topics & Keywords

Lung Cancer Treatments and Mutations Peptidase Inhibition and Analysis Cancer therapeutics and mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 31, Issue 27, pp. 3327-3334

DOI: 10.1200/jco.2012.44.2806

Field-Weighted Citation Impact: 217.61